The European Organization for Research and Treatment of Cancer (EORTC), a non-profit clinical research group, will use Foundation Medicine’s (FMI -1.3%) comprehensive genomic profiling (CGP) tests to optimize the selection of trial participants through its SPECTRA (Screening Patients for Efficient Clinical Trial Access) program.



I was just coming here to post the same link. Sounds like a good tidbit of news to me.

Maybe should have grabbed some calls earlier this morning when it dipped below $70/share briefly just before 10 am.